Hepatic arterial infusion chemotherapy combined with apatinib plus camrelizumab for advanced hepatocellular carcinoma with type Vp4 portal vein tumor thrombosis: a multicenter propensity score-matching analysis
For HCC with Vp4 type PVTT, the combination regimen of HAIC plus apatinib and camrelizumab demonstrates promising efficacy in reducing both intrahepatic tumor burden and thrombus progression, representing a potentially viable treatment approach with an acceptable safety profile.
Authors
- Fengtao Zhang (ORCID: https://orcid.org/0009-0003-7128-0126)
- M. Li
- H. Zhang
- Qian Cheng
- Dejun Xiong
- Q. Wei
- Sheng Zhong
- Ankang Shu
- Pingkang Chen
- Xiang Zheng
- Shaoteng Wu
- Feifeng Qiu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Tung Wah Hospital (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Shenzhen Sixth People's Hospital (CN)
- Zhuhai People's Hospital (CN)
- Chinese University of Hong Kong, Shenzhen (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- First Affiliated Hospital of Jinan University (CN)
- Anshan Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3389/fimmu.2026.1742116
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00